Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-09-15 07:00 |
Innate Pharma reports first half 2021 financial results and business update
|
English | 748.0 KB | ||
| 2021-09-07 07:00 |
Innate Pharma Organise une Conférence Téléphonique et un Webcast pour ses Rés…
|
French | 113.7 KB | ||
| 2021-09-07 07:00 |
Innate Pharma Announces Conference Call and Webcast for First Half 2021 Busines…
|
English | 110.9 KB | ||
| 2021-09-02 08:00 |
Monalizumab and ANKET™ Data Will be Presented at ESMO 2021 Virtual Congress
|
English | 151.4 KB | ||
| 2021-09-02 08:00 |
Des données sur monalizumab et ANKET™ seront présentées au congrès virtuel de l…
|
French | 139.0 KB | ||
| 2021-08-11 07:00 |
Nouveau Nombre d'Actions et de Droits de Vote d'Innate Pharma au 1er Aout 2021
|
French | 114.7 KB | ||
| 2021-08-11 07:00 |
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2021
|
English | 110.4 KB | ||
| 2021-07-12 07:00 |
Nouveau Nombre d'Actions et de Droits de Vote d'Innate Pharma au 1er Juillet 20…
|
French | 114.7 KB | ||
| 2021-07-12 07:00 |
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF JULY 1, 2021
|
English | 110.7 KB | ||
| 2021-07-06 07:00 |
RESULTATS DE L’ESSAI DE PHASE 2 FORCE, EVALUANT AVDORALIMAB CHEZ LES PATIENTS A…
|
French | 155.3 KB | ||
| 2021-07-06 07:00 |
Update on Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with Severe Pneu…
|
English | 162.9 KB | ||
| 2021-06-22 13:00 |
Innate Pharma présente des données préliminaires de l'essai TELLOMAK montrant u…
|
French | 208.2 KB | ||
| 2021-06-22 13:00 |
Innate Pharma presents preliminary data from TELLOMAK trial showing clinical re…
|
English | 149.4 KB | ||
| 2021-06-16 07:00 |
Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Comp…
|
English | 132.6 KB | ||
| 2021-06-16 07:00 |
Innate Pharma Présentera les Progres de sa Strategie Lors d'un Événement Virtue…
|
French | 142.7 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
